Earnings Summary

Xilio Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2023. On a quarterly growth basis, Xilio Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Xilio Therapeutics, Inc.’s net profit jumped 13.55% since last year same period to $-16.75Mn in the Q3 2023. On a quarterly growth basis, Xilio Therapeutics, Inc. has generated 13.47% jump in its net profits since last 3-months.

Xilio Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2023. On a quarterly growth basis, Xilio Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Xilio Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a 10.49% jump from last quarter’s estimates.

Xilio Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.64.

Xilio Therapeutics, Inc.’s earning per share (EPS) jumped 22.89% since last year same period to -0.64 in the Q1 2024. This indicates that the Xilio Therapeutics, Inc. has generated 22.89% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Xilio Therapeutics, Inc.’s return on assets (ROA) stands at -0.49.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Xilio Therapeutics, Inc.’s return on equity (ROE) stands at -1.07.